This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ogletree-Hughes, M. L. Articles by Moravec, C. S. Search for Related Content PubMed PubMed Citation Articles by Ogletree-Hughes, M. L. Articles by Moravec, C. S. Related Collections Congestive Heart failure - basic studies CV surgery: transplantation, ventricular assistance, cardiomyopathy

(Circulation. 2001;104:881.)
© 2001 American Heart Association, Inc.

Clinical Investigation and Reports

Mechanical Unloading Restores ß-Adrenergic Responsiveness and Reverses Receptor Downregulation in the Failing Human Heart

Monique L. Ogletree-Hughes, PhD; Linda B. Stull, PhD; Wendy E. Sweet, MS; Nicholas G. Smedira, MD; Patrick M. McCarthy, MD; Christine Schomisch Moravec, PhD

From the Center for Anesthesiology Research (M.L.O.-H., L.B.S., W.E.S., C.S.M.) and the Department of Thoracic and Cardiovascular Surgery (N.G.S., P.M.M.), The Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to Christine S. Moravec, PhD, The Cleveland Clinic Foundation, 9500 Euclid Ave, FF40, Cleveland, Ohio 44195. E-mail moravec{at}ccf.org

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—— Mechanical unloading of the failing human heart with a left ventricular assist device (LVAD) results in clinically documented reversal of chamber dilation and improvement of cardiac function. We tested the hypothesis that LVAD support normalizes the ability of cardiac muscle to respond to sympathetic nervous system stimulation by reversing the downregulation of ß-adrenergic receptors.

Methods and Results—— Human LV tissue was obtained from nonfailing hearts of unmatched organ donors and failing hearts at the time of transplantation, with or without LVAD. Baseline contractile parameters and inotropic response to a ß-adrenergic agonist were measured in isolated trabecular muscles. ß-Adrenergic receptor density was quantified by radioligand binding. Results showed a significant increase in the response to ß-adrenergic stimulation after LVAD (developed tension increased by 0.76±0.09 g/mm² in nonfailing, 0.38±0.07 in failing, and 0.68±0.10 in failing+LVAD; P<0.01), accompanied by an increased density of ß-adrenergic receptors (58.7±9.6 fmol/mg protein in nonfailing, 26.2±3.8 in failing, and 63.0±8.3 in failing+LVAD; P<0.05). These changes were unrelated to the duration of support.

Conclusions—— Data demonstrate that mechanically supporting the failing human heart with an LVAD can reverse the downregulation of ß-adrenergic receptors and restore the ability of cardiac muscle to respond to inotropic stimulation by the sympathetic nervous system. This indicates that functional impairment of cardiac muscle in human heart failure is reversible.

Key Words: heart failure • heart-assist device • receptors, adrenergic, beta • myocardial contraction

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Left ventricular assist devices (LVADs) are used to hemodynamically support heart failure patients awaiting transplantation. Studies from our group and others have demonstrated that mechanically unloading the heart with an LVAD can decrease heart size,^1,2 improve cardiac function,^3,4 decrease plasma neurohormones^5,6 and cytokines,⁷ and decrease ventricular expression of atrial natriuretic peptide⁸ and tumor necrosis factor-.⁹ It has been suggested that mechanical unloading provides enough improvement to make cardiac transplantation unnecessary in some patients,¹⁰ although others have disagreed with this contention.¹¹ Recent studies comparing tissue removed at LVAD implantation to the heart at transplantation have suggested that LVAD support improves the structure and function of cardiac myocytes, leading to decreased cell size,^12,13 increased contractility of cells^13,14 and muscles,¹⁵ improved function of intracellular organelles,^15,16 and altered gene expression.^15,17,18

An important compensatory mechanism for maintaining adequate tissue perfusion during functional impairment of the heart is augmentation of cardiac output by the sympathetic nervous system. Inability to respond to ß-adrenergic stimulation is a hallmark of the failing human heart.^19,20 Isolated muscles and myocytes from failing human hearts show a decreased inotropic response to ß-adrenergic agonists^21–23 and downregulation of ß-adrenergic receptors,^19–21 as well as uncoupling of the receptors from the downstream signaling pathway.^21,23

We tested the hypothesis that mechanically unloading the failing human heart with an LVAD can reverse the inability to respond to ß-adrenergic stimulation and the downregulation of ß-adrenergic receptors. A previous study by Dipla and colleagues¹⁴ demonstrated recovery of the inotropic response to isoproterenol in myocytes from LVAD-supported human hearts. In this study, we examined the inotropic responsiveness of LV trabecular muscles from LVAD-supported human hearts to isoproterenol and measured ß-adrenergic receptors in the same hearts. Data demonstrate recovery of both the ß-adrenergic inotropic response and ß-adrenergic receptor density after LVAD. This implies that the inability of the failing human heart to respond to the sympathetic nervous system is not irreversible.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Nonfailing human hearts were obtained from 15 organ donors whose hearts were unsuitable for transplantation but who had no history of cardiac disease. Failing human hearts were obtained from 23 transplant patients who had not been supported with an LVAD and 19 transplant patients who had been supported with an LVAD. All hearts were transported to the laboratory in cold cardioplegia, as previously described.^24,25

Once in the laboratory, tissue was placed in room-temperature Krebs-Henseleit buffer (composition [mmol/L]: NaCl 100.0, KCl 4.0, MgSO₄ 1.5, NaHCO₃ 20.0, NaH₂PO₄ 1.5, NaC₂H₃O₂ 20.0, glucose 10.0, ascorbic acid 0.1, and CaCl₂ 2.5, and insulin 5.0 IU/L) for dissection. Remaining tissue was frozen in liquid nitrogen. Protocols for tissue procurement were approved by the Institutional Review Board.

Isometric muscle contraction studies were performed according to established methods,^24,25 at 37°C, stimulation rate 1.0 Hz, duration 5 ms, and voltage 20% above threshold. Muscle length was adjusted until resting tension (RT) reached 0.5 to 1.0 g, and stimulation was initiated. Muscle length was adjusted in 0.1-mm increments until L_max (length associated with maximal developed tension [DT]) was reached, and function was allowed to stabilize for 45 to 60 minutes. Recorded contractile parameters included RT, DT, time to peak tension (TPT), time to half-relaxation (THR), maximal rate of tension rise (+dT/dt), and maximal rate of tension fall (-dT/dt).

A single dose of 1 µmol/L isoproterenol was used to assess ß-adrenergic responsiveness. The effects of isoproterenol on all isometric contractile parameters were recorded. There was no significant rundown of muscle function over the time course of these studies. Muscle cross-sectional area was calculated and used to normalize RT, DT, +dT/dt, and -dT/dt values. Muscles with cross-sectional area <0.2 mm² or >1.1 mm² or baseline DT <0.30 g/mm² were eliminated from the study.

Comparisons were made between nonfailing and failing hearts to define changes related to heart failure. Comparisons were then made between nonfailing hearts and failing hearts with an LVAD to detect changes in the direction of normal that were related to the LVAD.

ß-Adrenergic receptor density was quantified by radioligand binding with a modification of Bristow’s method.¹⁹ LV tissue from 8 nonfailing hearts, 8 failing hearts without LVAD, and 17 failing hearts with LVAD was homogenized in HEM buffer (composition [mmol/L]: HEPES 10.0 [pH 7.4], EGTA 5.0, MgCl₂ 12.5) with sucrose (250.0 mmol/L) and protease inhibitors. Membranes were washed with 0.5 mol/L KCl to remove myofilaments and centrifuged at 40 000g. The pellet was resuspended in HEM buffer with NaCl (100.0 mmol/L) and washed. Membranes were stored in HEM buffer plus 10% glycerol at -80°C until used for radioligand binding within 4 weeks of membrane preparation. Protein concentration was measured by the Lowry method. Seven increasing concentrations of ¹²⁵I-labeled cyanopindolol (3 to 240 pmol/L) were added to the membranes (protein concentration equal to 10% of the measured K_d) for the binding assay. Nonspecific binding was measured by competitive binding with 10^-4 mol/L propranolol. All reactions were run in triplicate. The mixture was incubated with shaking for 60 minutes at 37°C. Membranes were filtered onto glass fiber filter paper (Whatman, GF-C, Brandel Instruments) and washed 5 times with binding buffer (composition [mmol/L]: HEPES 50.0 [pH 7.4], EGTA 2.5, and MgCl₂ 12.5, and 0.1% BSA). Bound radioactivity was counted on a Micromedic Gamma Counter. Receptor density and dissociation constants were calculated from Scatchard plots. In separate experiments, we confirmed that there was no difference in the density or K_d of ß-adrenergic receptors measured in trabecular muscles versus LV free wall of the same heart.

Results are reported as mean±SEM. Data from multiple muscles per heart were averaged. Baseline contractile parameters, response to isoproterenol, and ß-adrenergic receptor densities and dissociation constants were compared by 1-way ANOVA followed by Student-Newman-Keuls post hoc testing. Relationships between duration of LVAD support and the inotropic response or receptor density were tested with Spearman correlations. Differences between groups were accepted as statistically significant if P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Table 1 summarizes information on patients from whom tissue was obtained. Table 2 presents information on each patient who had an LVAD, including the duration of support. Any patient who was taking ß-adrenergic blockers was eliminated from the study.

View this table: [in this window] [in a new window]   Table 1. Patient Information for Nonfailing and Failing Human Hearts

View this table: [in this window] [in a new window]   Table 2. Patient Information for Failing Hearts With an LVAD

Average contractile performance at baseline is presented in Table 3. Contractility was measured in 32 muscles from 10 nonfailing hearts, 55 muscles from 15 failing hearts without LVAD, and 41 muscles from 12 failing hearts with LVAD. There were no differences in muscle cross-sectional area or in any of the contractile parameters between groups.

View this table: [in this window] [in a new window]   Table 3. Comparison of Baseline Contractile Parameters at 37°C and 1.0 Hz

The inotropic response to isoproterenol was measured in 16 muscles from 9 nonfailing hearts, 38 muscles from 11 failing hearts without LVAD, and 27 muscles from 10 failing hearts with LVAD. The increase in DT produced by ß-adrenergic stimulation was significantly reduced in muscles from failing hearts without LVAD compared with muscles from nonfailing hearts (P<0.01; Figure 1). Muscles taken from failing hearts after LVAD support, however, showed inotropic responsiveness that was not significantly different from that of nonfailing muscles (Figure 1).

View larger version (23K): [in this window] [in a new window]   Figure 1. Response of muscles to 1 µmol/L isoproterenol. A, Change in RT; B, change in DT. Muscles from nonfailing hearts (NF), failing hearts without LVAD (Failing), and failing hearts with LVAD (Failing+LVAD). Data are shown as change from baseline (mean±SEM). **P<0.01 vs NF. n=No. of muscles/No. of hearts.

In response to isoproterenol, muscles from nonfailing hearts demonstrated the characteristic decreases in RT (Figure 1A), TPT, and THR and increases in +dT/dt and -dT/dt (Figure 2A through 2D). In muscles taken from failing hearts without LVAD, there was a blunting of the +dT/dt and -dT/dt responses to isoproterenol, which had recovered in hearts with LVAD (Figure 2C and 2D; P<0.05). The TPT response to isoproterenol appeared to be diminished in failing hearts without LVAD (Figure 2A), but this was not statistically significant. The THR (Figure 2B) and RT responses did not differ in the 3 groups of muscles.

View larger version (34K): [in this window] [in a new window]   Figure 2. Response of muscles to 1 µmol/L isoproterenol. Muscles from nonfailing hearts (NF), failing hearts without LVAD (Failing), and failing hearts with LVAD (Failing+LVAD). A, TPT; B, THR; C, +dT/dt; and D, -dT/dt. Data are shown as change from baseline contraction (mean±SEM). *P<0.05 vs NF. n=No. of muscles/No. of hearts.

Figure 3A and 3B show a typical saturation binding experiment (A) and Scatchard analysis (B) for 1 failing heart with LVAD. Figure 3C summarizes the quantification of receptor density, which was decreased in failing hearts without LVAD compared with nonfailing hearts (P<0.05). In LVAD-supported failing hearts, however, ß-adrenergic receptor density was not different from that in nonfailing hearts. There was no difference in the K_d among the groups, with an average of 15.6±2.2 pmol/L in nonfailing hearts, 15.5±1.6 pmol/L in failing hearts without LVAD, and 22.6±2.6 pmol/L in LVAD-supported hearts.

View larger version (18K): [in this window] [in a new window]   Figure 3. ß-Adrenergic receptor measurements. Saturation binding (A) and Scatchard analysis (B) from 1 failing heart with LVAD. C, Receptor density of nonfailing hearts (NF), failing hearts without LVAD (Failing), and failing hearts with LVAD (Failing+LVAD). *P<0.05 vs NF. CYP indicates cyanopindolol.

Figure 4 shows the response to isoproterenol (A) and the ß-adrenergic receptor density (B) in failing patients without LVAD, divided into those who were receiving ß-agonist therapy at the time of transplantation and those who were not. There was no significant difference between these 2 groups of patients.

View larger version (15K): [in this window] [in a new window]   Figure 4. Inotropic response to isoproterenol (A) and ß-adrenergic receptor density (B) in failing patients without LVAD. Patients were subdivided into those who were receiving ß-agonist therapy at time of transplantation and those who were not.

Figure 5 shows the relationships, on a heart-by-heart basis, between duration of LVAD support and the inotropic response to isoproterenol (A) or the receptor density (B). Panel C illustrates the relationship between receptor density and inotropic response. Duration of mechanical support does not completely predict either the response to inotropic stimulation or the density of ß-adrenergic receptors in the patients studied. Receptor density alone also does not predict the magnitude of the inotropic response.

View larger version (21K): [in this window] [in a new window]   Figure 5. Relationship between (A) duration of LVAD and response to isoproterenol; (B) duration of LVAD and receptor density; and (C) receptor density and response to isoproterenol. Numbers next to each point indicate patient number and correspond to numbers in Table 2.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We compared cardiac muscle contractility at baseline and after inotropic stimulation by isoproterenol, as well as the density of ß-adrenergic receptors, in nonfailing human hearts and failing human hearts with or without LVAD. We observed no decrement in contractile function of isolated trabecular muscles from patients with heart failure compared with muscles from nonfailing hearts at 37°C and 1.0 Hz stimulation. The absolute DT of our muscles was similar in magnitude to that reported previously by us^24,25 and by others.²⁶ Early studies of failing human muscles reported decreased DT²⁷ or prolonged TPT and THR.²³ More recently, studies performed at physiological temperatures and stimulation rates showed no change in DT²⁸ or a decrease only at elevated stimulation frequencies.²⁹ LVAD treatment of the failing heart had no effect on any of the contractile parameters at L_max (Table 3).

Although muscles taken from failing human hearts do not consistently demonstrate reduced contractility, there is widespread agreement that the ß-adrenergic response is depressed.^19–23 Trabecular muscles and myocytes show a diminished ability to increase contraction in response to ß-adrenergic agonists.^21–23 The density of ß-adrenergic receptors is decreased, and alterations in downstream signaling have been documented.^21,23 We have shown that unloading the failing human heart with an LVAD can reverse this phenotype. Muscles taken from LVAD hearts produced an inotropic response to isoproterenol that was similar to that measured in nonfailing muscles and significantly better than that observed in muscles from failing hearts without LVAD. This confirms the report by Dipla and coworkers,¹⁴ who demonstrated that ß-adrenergic responsiveness of isolated myocytes could be recovered with LVAD support. We examined the relationship between duration of support and recovery of the inotropic response (Figure 4A). Although patients supported for a longer time had greater recovery of the inotropic response, this relationship was not linear or statistically significant, suggesting that factors in addition to duration contribute to variability in recovery of the inotropic response.

We also measured ß-adrenergic receptor density in the same hearts. In hearts with LVAD support, the density of ß-adrenergic receptors was comparable to that in nonfailing hearts (Figure 3C). Analysis of the relationship between duration and receptor density (Figure 4B) suggested that there was no correlation. In fact, receptor density was actually highest in a heart supported for only 49 days and was considerably lower in hearts supported for significantly longer. We also examined the relationship between receptor density and the inotropic response to isoproterenol (Figure 4C). This relationship was not significant in this population of patients, suggesting that portions of the signaling pathway (downstream of the receptor or involved in the more basic mechanisms of excitation-contraction coupling) play a greater role in dictating the response to inotropic stimulation and should be evaluated for recovery after mechanical support. Given the recent demonstration of the role of ryanodine receptor hyperphosphorylation in the diminished ß-adrenergic response of the failing heart and its recovery after LVAD,³⁰ it is clear that ß-adrenergic receptors are only the first in a long line of signaling molecules whose potential to recover should be examined.

Although we have shown that mechanical unloading may result in recovery of the ß-adrenergic response, our data do not address the mechanism for this change. One possibility is that normalization of plasma neurohormones, which has been shown in LVAD patients,^5,6 results in reversal of ß-adrenergic receptor downregulation. In addition, LVAD support has also been shown to cause a decrease in both plasma⁷ and cardiac⁹ cytokine levels, which could also contribute to the improved response. Several studies have demonstrated that tumor necrosis factor- decreases the ß-adrenergic response in animal cardiac muscle.³¹ It must also be noted, however, that LVAD implantation in most patients is accompanied by a change in the medical regimen. Patients who had previously been supported with ß-adrenergic agonists such as dobutamine may not require this type of inotropic support on the LVAD. To address the question of whether withdrawal of ß-agonist therapy could explain the increased response to ß-adrenergic stimulation, we divided our population of failing patients without LVAD support into 2 groups: those who were receiving ß-agonist therapy at the time of transplantation and those who were not. Data presented in Figure 4 clearly indicate that a lack of ß-agonist therapy does not necessarily result in an improved inotropic response to isoproterenol or an increase in ß-adrenergic receptor density. This lends support to our contention that recovery of the ß-adrenergic response in LVAD patients is related to mechanical unloading and not caused simply by the withdrawal of inotropic support.

In summary, we have shown that LVAD support of the failing human heart results in recovery of the ability of cardiac muscle to respond to sympathetic nervous system stimulation and increased density of ß-adrenergic receptors. Reversal of the inotropic response and receptor density may be related to either mechanical unloading of the heart or decreased circulating neurohormones. On the basis of analyses of the relationship between LVAD duration and the recovery of inotropic responsiveness or receptor density, we propose that factors other than duration predict the extent of recovery and that further investigation must examine the reversal of downstream elements of the ß-adrenergic signaling pathway in these patients. Nevertheless, this study demonstrates that downregulation of ß-adrenergic receptors, which has long been a hallmark of the failing human heart, is not an irreversible phenomenon and supports the contention that the failing human heart retains the capacity for recovery.

	Acknowledgments

 
Dr Ogletree-Hughes was supported by a National Research Service Award (1-F31-HL-90052-01A1) and is currently supported by an American Heart Association (AHA) postdoctoral fellowship (Ohio Valley Affiliate No. 0020389B). Dr Moravec is an Established Investigator of the AHA. The authors acknowledge the assistance of the cardiac transplantation teams, pathology residents, and Dr Norman B. Ratliff for help in procuring failing human heart tissue for research. We thank Life Banc of Northeastern Ohio for nonfailing human heart tissue.

Received March 27, 2001; revision received June 20, 2001; accepted June 21, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Levin HR, Oz MC, Chen JM, et al. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation. 1995; 91: 2717–2720.[Abstract/Free Full Text]

2. Nakatani S, McCarthy PM, Kottke-Marchant K, et al. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable left ventricular assist device. J Am Coll Cardiol. 1996; 27: 894–901.[Abstract]

3. McCarthy PM, James KB, Savage RM, et al. Implantable left ventricular assist device: approaching an alternative for end-stage heart failure. Circulation. 1994; 90 (suppl II): II-83–II-86.

4. Frazier OH, Benedict CR, Radovancevic B, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg. 1996; 62: 675–682.[Abstract/Free Full Text]

5. Estrada-Quintero T, Uretsky BF, Murali S, et al. Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. Chest. 1995; 107: 1499–1503.[Abstract/Free Full Text]

6. James KB, McCarthy PM, Thomas JD, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation. 1995; 92 (suppl II): II-191–II-195.

7. Goldtstein DJ, Moazami N, Seldomridge A, et al. Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. Ann Thorac Surg. 1997; 63: 971–974.[Abstract/Free Full Text]

8. Altemose GT, Gritsus V, Jeevanandam V, et al. Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy. J Heart Lung Transplant. 1997; 16: 765–773.[Medline] [Order article via Infotrieve]

9. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor- in failing human myocardium after mechanical circulatory support. Circulation. 1999; 100: 1189–1193.[Abstract/Free Full Text]

10. Muller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997; 96: 542–549.[Abstract/Free Full Text]

11. Mancini D, Goldsmith R, Levin H, et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation. 1998; 98: 1178–1183.[Abstract/Free Full Text]

12. Jacquet L, Zerbe T, Stein KL, et al. Evolution of human cardiac myocyte dimension during prolonged mechanical support. J Thorac Cardiovasc Surg. 1991; 101: 256–259.[Abstract]

13. Zafeiridis A, Jeevanandam V, Houser SR, et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998; 98: 656–662.[Abstract/Free Full Text]

14. Dipla K, Mattiello J, Jeevanandam V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998; 97: 2316–2322.[Abstract/Free Full Text]

15. Heerdt PM, Holmes JW, Cai B, et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000; 102: 2713–2719.[Abstract/Free Full Text]

16. Lee SH, Doliba N, Osbakken M, et al. Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg. 1998; 116: 344–349.[Abstract/Free Full Text]

17. Bartling B, Milting H, Schumann H, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999; 100 (suppl II): II-216–II-223.

18. Takeishi Y, Jalili T, Hoit BD, et al. Alterations in Ca²⁺ cycling proteins and Gq signaling after left ventricular assist device support in failing human hearts. Cardiovasc Res. 2000; 45: 883–888.[Abstract/Free Full Text]

19. Bristow MR, Ginsburg KS, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med. 1982; 307: 205–211.[Abstract]

20. Engelhardt S, Bohm M, Erdmann E, et al. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol. 1996; 27: 146–154.[Abstract]

21. Bristow MR, Anderson FL, Port JD, et al. Differences in ß-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991; 84: 1024–1039.[Abstract/Free Full Text]

22. Davies CH, Davia K, Bennett JG, et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 1995; 92: 2540–2549.[Abstract/Free Full Text]

23. Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987; 75: 331–339.[Abstract/Free Full Text]

24. Sprung J, Schuetz S, Stewart RW, et al. Effects of ketamine on the contractility of failing and nonfailing human heart muscles in vitro. Anesthesiology. 1998; 88: 1202–1210.[Medline] [Order article via Infotrieve]

25. Sprung J, Ogletree-Hughes ML, Moravec CS. The effects of etomidate on the contractility of failing and nonfailing human heart muscle. Anesth Analg. 2000; 91: 68–75.[Abstract/Free Full Text]

26. Vahl CF, Timek T, Bonz A, et al. Length dependence of calcium and force transients in normal and failing human myocardium. J Mol Cell Cardiol. 1998; 30: 957–966.[Medline] [Order article via Infotrieve]

27. Hasenfuss G, Mulieri LA, Leavitt BJ, et al. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res. 1992; 70: 1225–1232.[Abstract/Free Full Text]

28. Pieske B, Sutterlin M, Schmidt-Schweda S, et al. Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. J Clin Invest. 1996; 98: 764–776.[Medline] [Order article via Infotrieve]

29. Hasenfuss G, Reinecke H, Studer R, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca²⁺-ATPase in failing and nonfailing human myocardium. Circ Res. 1994; 75: 434–442.[Abstract/Free Full Text]

30. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000; 101: 365–376.[Medline] [Order article via Infotrieve]

31. Chung MK, Gulick TS, Rotondo RE, et al. Mechanism of cytokine inhibition of ß-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Circ Res. 1990; 67: 753–763.[Abstract/Free Full Text]

This article has been cited by other articles:

				E. Z. Gorodeski, E. C. Chu, J. R. Reese, M. H. Shishehbor, E. Hsich, and R. C. Starling Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure Circ Heart Fail, July 1, 2009; 2(4): 320 - 324. [Abstract] [Full Text] [PDF]

				H. Brinks, H. Tevaearai, C. Muhlfeld, D. Bertschi, B. Gahl, T. Carrel, and M.-N. Giraud Contractile function is preserved in unloaded hearts despite atrophic remodeling. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 742 - 746. [Abstract] [Full Text] [PDF]

				J. Wang, M. Tsukashita, T. Nishina, A. Marui, E. Yoshikawa, H. Muranaka, S. Matsuoka, and T. Ikeda Chronic partial unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in failing rat hearts. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 465 - 470. [Abstract] [Full Text] [PDF]

				G. K.R. Soppa, J. Lee, M. A. Stagg, L. E. Felkin, P. J.R. Barton, U. Siedlecka, S. Youssef, M. H. Yacoub, and C. M.N. Terracciano Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure Cardiovasc Res, March 1, 2008; 77(4): 695 - 706. [Abstract] [Full Text] [PDF]

				J. Wang, A. Marui, T. Ikeda, and M. Komeda Partial left ventricular unloading reverses contractile dysfunction and helps recover gene expressions in failing rat hearts Interactive CardioVascular and Thoracic Surgery, February 1, 2008; 7(1): 27 - 31. [Abstract] [Full Text] [PDF]

				T. A. Bullard, T. L. Protack, F. Aguilar, S. Bagwe, H. T. Massey, and B. C. Blaxall Identification of Nogo as a novel indicator of heart failure Physiol Genomics, January 17, 2008; 32(2): 182 - 189. [Abstract] [Full Text] [PDF]

				C. Perrino, J. N. Schroder, B. Lima, N. Villamizar, J. J. Nienaber, C. A. Milano, and S. V. Naga Prasad Dynamic Regulation of Phosphoinositide 3-Kinase-{gamma} Activity and -Adrenergic Receptor Trafficking in End-Stage Human Heart Failure Circulation, November 27, 2007; 116(22): 2571 - 2579. [Abstract] [Full Text] [PDF]

				N. R. Stob, D. R. Seals, J. Jensen, M. A. van Baak, A. J. Steig, R. C. Lindstrom, B. T. Bikman, and C. Bell Autonomic Neuroscience: Increased thermogenic responsiveness to intravenous {beta}-adrenergic stimulation in habitually exercising humans is not related to skeletal muscle {beta}2-adrenergic receptor density Exp Physiol, September 1, 2007; 92(5): 823 - 830. [Abstract] [Full Text] [PDF]

				A. Noda, H. Izawa, H. Asano, S. Nakata, A. Hirashiki, Y. Murase, S. Iino, K. Nagata, T. Murohara, Y. Koike, et al. Beneficial Effect of Bilevel Positive Airway Pressure on Left Ventricular Function in Ambulatory Patients With Idiopathic Dilated Cardiomyopathy and Central Sleep Apnea-Hypopnea: A Preliminary Study Chest, June 1, 2007; 131(6): 1694 - 1701. [Abstract] [Full Text] [PDF]

				S. Maybaum, D. Mancini, S. Xydas, R. C. Starling, K. Aaronson, F. D. Pagani, L. W. Miller, K. Margulies, S. McRee, O.H. Frazier, et al. Cardiac Improvement During Mechanical Circulatory Support: A Prospective Multicenter Study of the LVAD Working Group Circulation, May 15, 2007; 115(19): 2497 - 2505. [Abstract] [Full Text] [PDF]

				N. Okuda, T. Ito, N. Emura, M. Suwa, T. Hayashi, H. Yoneda, and Y. Kitaura Depressed Myocardial Contractile Reserve in Patients With Obstructive Sleep Apnea Assessed by Tissue Doppler Imaging With Dobutamine Stress Echocardiography Chest, April 1, 2007; 131(4): 1082 - 1089. [Abstract] [Full Text] [PDF]

				P. K. Pandalai, C. F. Bulcao, W. H. Merrill, and S. A. Akhter Restoration of myocardial {beta}-adrenergic receptor signaling after left ventricular assist device support J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 975 - 980. [Abstract] [Full Text] [PDF]

				J. Wohlschlaeger, K. J. Schmitz, C. Schmid, K. W. Schmid, P. Keul, A. Takeda, S. Weis, B. Levkau, and H. A. Baba Reverse remodeling following insertion of left ventricular assist devices (LVAD): A review of the morphological and molecular changes Cardiovasc Res, December 1, 2005; 68(3): 376 - 386. [Abstract] [Full Text] [PDF]

				G. Matsumiya, O. Monta, N. Fukushima, Y. Sawa, T. Funatsu, K. Toda, and H. Matsuda Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 699 - 704. [Abstract] [Full Text] [PDF]

				D. Mancini and D. Burkhoff Mechanical Device-Based Methods of Managing and Treating Heart Failure Circulation, July 19, 2005; 112(3): 438 - 448. [Abstract] [Full Text] [PDF]

				T. Mizuno, R. D. Weisel, and R.-K. Li Reloading the heart: A new animal model of left ventricular assist device removal J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 99 - 106. [Abstract] [Full Text] [PDF]

				K. B. Margulies, S. Matiwala, C. Cornejo, H. Olsen, W. A. Craven, and D. Bednarik Mixed Messages: Transcription Patterns in Failing and Recovering Human Myocardium Circ. Res., March 18, 2005; 96(5): 592 - 599. [Abstract] [Full Text] [PDF]

				S. Klotz, A. Barbone, S. Reiken, J. W. Holmes, Y. Naka, M. C. Oz, A. R. Marks, and D. Burkhoff Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties J. Am. Coll. Cardiol., March 1, 2005; 45(5): 668 - 676. [Abstract] [Full Text] [PDF]

				T. Takaseya, M. Ishimatsu, E. Tayama, A. Nishi, T. Akasu, and S. Aoyagi Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2239 - 2246. [Abstract] [Full Text] [PDF]

				K. W. Chaudhary, E. I. Rossman, V. Piacentino III, A. Kenessey, C. Weber, J. P. Gaughan, K. Ojamaa, I. Klein, D. M. Bers, S. R. Houser, et al. Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart J. Am. Coll. Cardiol., August 18, 2004; 44(4): 837 - 845. [Abstract] [Full Text] [PDF]

				B. Pieske Reverse remodeling in heart failure - fact or fiction? Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D66 - D78. [Abstract] [Full Text] [PDF]

				K. B. Margulies Blocking Stretch-Induced Myocardial Remodeling Circ. Res., November 28, 2003; 93(11): 1020 - 1022. [Full Text] [PDF]

				I. P. Uray, J. H. Connelly, O.H. Frazier, H. Taegtmeyer, and P. J.A. Davies Mechanical unloading increases caveolin expression in the failing human heart Cardiovasc Res, July 1, 2003; 59(1): 57 - 66. [Abstract] [Full Text] [PDF]

				B. S. McGowan, C. B. Scott, A. Mu, R. J. McCormick, D. P. Thomas, and K. B. Margulies Unloading-induced remodeling in the normal and hypertrophic left ventricle Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2061 - H2068. [Abstract] [Full Text] [PDF]

				Y. Kaneko, J. S. Floras, K. Usui, J. Plante, R. Tkacova, T. Kubo, S.-i. Ando, and T. D. Bradley Cardiovascular Effects of Continuous Positive Airway Pressure in Patients with Heart Failure and Obstructive Sleep Apnea N. Engl. J. Med., March 27, 2003; 348(13): 1233 - 1241. [Abstract] [Full Text] [PDF]

				X. Chen, V. Piacentino III, S. Furukawa, B. Goldman, K. B. Margulies, and S. R. Houser L-Type Ca2+ Channel Density and Regulation Are Altered in Failing Human Ventricular Myocytes and Recover After Support With Mechanical Assist Devices Circ. Res., September 20, 2002; 91(6): 517 - 524. [Abstract] [Full Text] [PDF]

				W. F. Saavedra, R. S. Tunin, N. Paolocci, T. Mishima, G. Suzuki, C. W. Emala, P. A. Chaudhry, P. Anagnostopoulos, R. C. Gupta, H. N. Sabbah, et al. Reverse remodeling and enhancedadrenergic reserve from passive externalsupport in experimental dilated heart failure J. Am. Coll. Cardiol., June 19, 2002; 39(12): 2069 - 2076. [Abstract] [Full Text] [PDF]

				N. de Jonge, D. F. van Wichen, M. E. I. Schipper, J. R. Lahpor, F. H. J. Gmelig-Meyling, E. O. Robles de Medina, and R. A. de Weger Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading: An immunohistochemical analysis of the contractile myofilaments J. Am. Coll. Cardiol., March 20, 2002; 39(6): 963 - 969. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ogletree-Hughes, M. L. Articles by Moravec, C. S. Search for Related Content PubMed PubMed Citation Articles by Ogletree-Hughes, M. L. Articles by Moravec, C. S. Related Collections Congestive Heart failure - basic studies CV surgery: transplantation, ventricular assistance, cardiomyopathy